Receptopharm, Inc. Expands Antiviral Clinical Research To South America
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that its drug discovery division, ReceptoPharm, is expanding the clinical research of its lead antiviral drug candidate, RPI-MN, into South America. RPI-MN was used in early clinical studies in Mexico and Peru.